Saluda Medical develops and commercializes the Evoke® System, a closed-loop spinal cord stimulation device for managing chronic pain.

SiteOne Therapeutics is a biopharmaceutical company developing selective, small molecule ion channel modulators for treating sensory hyperexcitability disorders like pain and chronic cough.

Current is a consumer fintech banking platform that offers accessible financial solutions, including faster paycheck access and secured credit-building cards.

Archer Aviation develops hybrid VTOL aircraft for defense applications, leveraging rapid aircraft development and AI systems integration.

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Amp Robotics provides AI-driven robotic systems for waste sorting on an "as a service" model, charging per ton of waste sorted.

AMP is a Sydney-based eCommerce platform that provides an interconnected, end-to-end solution for eCommerce merchants, aiming to consolidate multiple apps into one manageable system.

Beta Bionics is a medical technology company that designs, develops, and commercializes autonomous insulin delivery systems to streamline diabetes management.

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Crisp provides an AI-driven Collaborative Commerce platform that optimizes supply chains, reduces waste, and improves profitability for consumer packaged goods (CPG) brands.

Trace Machina develops a simulation testing platform called NativeLink to test and validate software for autonomous systems like self-driving cars and robotics.

Mindset Care simplifies Social Security Disability benefits applications for individuals with serious mental illnesses using AI-driven solutions and experienced disability attorneys.

Tabby is a buy now, pay later platform that has raised $200 million in a Series D funding round, with plans to expand its product offerings and potentially prepare for an IPO.

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.